HomeCompareBDSI vs ADC

BDSI vs ADC: Dividend Comparison 2026

BDSI yields 35.78% · ADC yields 4.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 BDSI wins by $4.8K in total portfolio value
10 years
BDSI
BDSI
● Live price
35.78%
Share price
$5.59
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$183.7K
Annual income
$28,272.37
Full BDSI calculator →
ADC
Agree Realty Corporation
● Live price
4.13%
Share price
$74.97
Annual div
$3.10
5Y div CAGR
40.4%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$178.9K
Annual income
$80,797.29
Full ADC calculator →

Portfolio growth — BDSI vs ADC

📍 BDSI pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodBDSIADC
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, BDSI + ADC cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
BDSI pays
ADC pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

BDSI
Annual income on $10K today (after 15% tax)
$3,041.14/yr
After 10yr DRIP, annual income (after tax)
$24,031.51/yr
ADC
Annual income on $10K today (after 15% tax)
$351.36/yr
After 10yr DRIP, annual income (after tax)
$68,677.70/yr
At 15% tax rate, ADC beats the other by $44,646.18/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of BDSI + ADC for your $10,000?

BDSI: 50%ADC: 50%
100% ADC50/50100% BDSI
Portfolio after 10yr
$181.3K
Annual income
$54,534.83/yr
Blended yield
30.07%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ADC right now

BDSI
Analyst Ratings
9
Buy
2
Hold
Consensus: Buy
Altman Z
2.8
Piotroski
6/9
ADC
Analyst Ratings
1
Strong
22
Buy
9
Hold
Consensus: Buy
Price Target
$81.06
+8.1% upside vs current
Range: $75.00 — $84.50
Altman Z
1.6
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

BDSI buys
0
ADC buys
0
No recent congressional trades found for BDSI or ADC in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricBDSIADC
Forward yield35.78%4.13%
Annual dividend / share$2.00$3.10
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.4%
Portfolio after 10y$183.7K$178.9K
Annual income after 10y$28,272.37$80,797.29
Total dividends collected$133.5K$156.7K
Payment frequencyquarterlymonthly
SectorStockREIT
Analyst consensusBuyBuy

Year-by-year: BDSI vs ADC ($10,000, DRIP)

YearBDSI PortfolioBDSI Income/yrADC PortfolioADC Income/yrGap
1← crossover$14,278$3,577.82$10,990$580.36+$3.3KBDSI
2$20,051$4,774.15$12,301$860.26+$7.8KBDSI
3$27,721$6,266.08$14,104$1,298.62+$13.6KBDSI
4$37,758$8,096.12$16,691$2,008.16+$21.1KBDSI
5$50,707$10,305.96$20,580$3,205.09+$30.1KBDSI
6$67,191$12,934.95$26,754$5,330.02+$40.4KBDSI
7$87,913$16,018.70$37,196$9,345.14+$50.7KBDSI
8$113,655$19,587.81$56,244$17,523.09+$57.4KBDSI
9$145,277$23,666.62$94,286$35,736.21+$51.0KBDSI
10$183,719$28,272.37$178,949$80,797.29+$4.8KBDSI

BDSI vs ADC: Complete Analysis 2026

BDSIStock

BioDelivery Sciences International, Inc., a specialty pharmaceutical company, engages in the development and commercialization of pharmaceutical products for chronic conditions in the United States and internationally. The company provides its products based on its patented BioErodible MucoAdhesive drug-delivery technology, a small erodible polymer film for application to the buccal mucosa, as well as other drug delivery technologies. It offers BELBUCA, a buprenorphine buccal film for the treatment of chronic pain; and Symproic, a peripherally acting mu-opioid receptor antagonist for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain, including patients with chronic pain related to prior cancer or its treatment who do not require frequent opioid dosage escalation. The company also provides ELYXYB, a celecoxib oral solution for the treatment of migraine with or without aura in adults; and ONSOLIS, a fentanyl buccal soluble film for the management of breakthrough pain in cancer patients. BioDelivery Sciences International, Inc. was incorporated in 1997 and is headquartered in Raleigh, North Carolina. As of March 18, 2022, BioDelivery Sciences International, Inc. operates as a subsidiary of Collegium Pharmaceutical, Inc.

Full BDSI Calculator →

ADCREIT

Agree Realty Corporation is a publicly traded real estate investment trust primarily engaged in the acquisition and development of properties net leased to industry-leading retail tenants. As of September 30, 2020, the Company owned and operated a portfolio of 1,027 properties, located in 45 states and containing approximately 21.0 million square feet of gross leasable area. The Company's common stock is listed on the New York Stock Exchange under the symbol ADC.

Full ADC Calculator →
📬

Get this BDSI vs ADC comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

BDSI vs SCHDBDSI vs JEPIBDSI vs OBDSI vs KOBDSI vs MAINBDSI vs NNNBDSI vs EPRTBDSI vs FCPT

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.